Sanofi has unveiled strong Phase III results for anti-CD38 targeted immunotherapy Sarclisa (isatuximab), as an addition to second-line therapy for multiple myeloma, which will help it gain a toehold in a highly competitive market.
The results strengthen its use case in this later-line setting ahead of gaining further approvals in earlier-stage disease. Updated results...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
